Patient-reported outcomes in studies comparing integrated PC with usual care in patients with hematologic malignancies
| Study . | Design . | N . | Hematologic malignancy . | Outcome . | Time . | Scales . | P . | Conclusions . |
|---|---|---|---|---|---|---|---|---|
| El-Jawahri et al8 | RCT comparing integrated PC to usual care in patients undergoing intensive chemotherapy for AML | 160 | AML | Standardized mean difference between scores | 2 wk | FACT-L HADS-A HADS-D PHQ-9 ESAS PCL | .04 .02 .02 .04 .12 .01 | Significant difference in change of scores over 12 weeks for multiple scales except ESAS, favoring integrated PC group. |
| El-Jawahri et al10,11 | RCT comparing integrated PC to usual care in patients undergoing HSCT (single site) | 160 | HSCT | Standardized mean difference between scores | 2 wk 3 mo 6 mo | Patients FACT-BMT FACT-F HADS-A HADS-D PHQ-9 ESAS Caregivers CGO-QOL CGO-QOL-C CGO-QOL-AF HADS-A HADS-D PHQ9 FACT-BMT FACT-F HADS-A HADS-D PHQ-9 ESAS PTSDC-C FACT-BMT FACT-F HADS-A HADS-D PHQ-9 PCL | .02 .04 <.001 .008 .10 .02 .24 .02 .02 .95 .03 .99 .048 .20 .13 .002 .002 .21 .002 .346 .957 .267 .024 .027 .013 | Significant difference in change of patient scores over 2 weeks, 3 months, and 6 months for multiple scales, favoring early PC group. Significant difference in change of caregiver scores over 2 weeks for CGO-QOL coping and administrative/financial subscales and HADS-D, favoring integrated PC group. |
| El-Jawahri et al12 | RCT comparing early PC to usual care in patients undergoing HSCT (multisite) | 360 | HSCT | Standardized mean difference between scores | 2 wk | FACT-BMT FACT-F HADS-A HADS-D PCL ESAS | <.001 .014 NS .041 .022 .018 | Significant difference in change of patient scores over 2 weeks, favoring integrated PC group. |
| Study . | Design . | N . | Hematologic malignancy . | Outcome . | Time . | Scales . | P . | Conclusions . |
|---|---|---|---|---|---|---|---|---|
| El-Jawahri et al8 | RCT comparing integrated PC to usual care in patients undergoing intensive chemotherapy for AML | 160 | AML | Standardized mean difference between scores | 2 wk | FACT-L HADS-A HADS-D PHQ-9 ESAS PCL | .04 .02 .02 .04 .12 .01 | Significant difference in change of scores over 12 weeks for multiple scales except ESAS, favoring integrated PC group. |
| El-Jawahri et al10,11 | RCT comparing integrated PC to usual care in patients undergoing HSCT (single site) | 160 | HSCT | Standardized mean difference between scores | 2 wk 3 mo 6 mo | Patients FACT-BMT FACT-F HADS-A HADS-D PHQ-9 ESAS Caregivers CGO-QOL CGO-QOL-C CGO-QOL-AF HADS-A HADS-D PHQ9 FACT-BMT FACT-F HADS-A HADS-D PHQ-9 ESAS PTSDC-C FACT-BMT FACT-F HADS-A HADS-D PHQ-9 PCL | .02 .04 <.001 .008 .10 .02 .24 .02 .02 .95 .03 .99 .048 .20 .13 .002 .002 .21 .002 .346 .957 .267 .024 .027 .013 | Significant difference in change of patient scores over 2 weeks, 3 months, and 6 months for multiple scales, favoring early PC group. Significant difference in change of caregiver scores over 2 weeks for CGO-QOL coping and administrative/financial subscales and HADS-D, favoring integrated PC group. |
| El-Jawahri et al12 | RCT comparing early PC to usual care in patients undergoing HSCT (multisite) | 360 | HSCT | Standardized mean difference between scores | 2 wk | FACT-BMT FACT-F HADS-A HADS-D PCL ESAS | <.001 .014 NS .041 .022 .018 | Significant difference in change of patient scores over 2 weeks, favoring integrated PC group. |
Bold typeface indicates significant differences found between intervention and control groups.
CGO-QOL, CareGiver Oncology Quality of Life Questionnaire; CGO-QOL-AF, CareGiver Oncology Quality of Life Questionnaire Administrative and Financial subscale; CGO-QOL-C, CareGiver Oncology Quality of Life Questionnaire Coping subscale; ESAS, Edmonton Symptom Assessment System; FACT-L, Functional Assessment of Cancer Therapy—Leukemia; HADS-A, Hospital Anxiety and Depression Scale Anxiety subscale; HADS-D, Hospital Anxiety and Depression Scale Depression subscale; PCL, Post-Traumatic Distress Checklist—Civilian; PHQ-9, Patient Health Questionnaire 9; RCT, randomized clinical trial.